- Home
- YOU vs DYN Comparison
YOU vs DYN Comparison
Compare YOU & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOU
- DYN
- Stock Information
- Founded
- YOU 2010
- DYN 1984
- Country
- YOU United States
- DYN United States
- Employees
- YOU N/A
- DYN N/A
- Industry
- YOU Computer Software: Prepackaged Software
- DYN Medicinal Chemicals and Botanical Products
- Sector
- YOU Technology
- DYN Health Care
- Exchange
- YOU Nasdaq
- DYN Nasdaq
- Market Cap
- YOU 2.2B
- DYN 2.6B
- IPO Year
- YOU 2021
- DYN 2020
- Fundamental
- Price
- YOU $24.00
- DYN $13.95
- Analyst Decision
- YOU Buy
- DYN Strong Buy
- Analyst Count
- YOU 5
- DYN 10
- Target Price
- YOU $34.20
- DYN $50.78
- AVG Volume (30 Days)
- YOU 1.6M
- DYN 2.2M
- Earning Date
- YOU 02-26-2025
- DYN 03-04-2025
- Dividend Yield
- YOU 3.28%
- DYN N/A
- EPS Growth
- YOU 2686.35
- DYN N/A
- EPS
- YOU 0.86
- DYN N/A
- Revenue
- YOU $735,183,000.00
- DYN N/A
- Revenue This Year
- YOU $26.16
- DYN N/A
- Revenue Next Year
- YOU $14.26
- DYN N/A
- P/E Ratio
- YOU $26.06
- DYN N/A
- Revenue Growth
- YOU 28.78
- DYN N/A
- 52 Week Low
- YOU $16.05
- DYN $13.07
- 52 Week High
- YOU $38.88
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- YOU 47.32
- DYN 40.51
- Support Level
- YOU $21.67
- DYN $13.59
- Resistance Level
- YOU $24.52
- DYN $14.50
- Average True Range (ATR)
- YOU 0.84
- DYN 0.95
- MACD
- YOU 0.08
- DYN 0.34
- Stochastic Oscillator
- YOU 68.21
- DYN 30.57
About YOU Clear Secure Inc.
Clear Secure Inc is an identity company making experiences safer and easier digitally and physically. It is involved in the creation of a frictionless travel experience while enhancing security. Its secure identity platform uses biometrics to automate the identity verification process through lanes in airports which helps to make the travel experience safe and easy.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.